Evidence map›Paper›PMID 18197262›Full record

ArticlePloS one2008

Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?

Jo N Fleming, Richard A Nash, D O McLeod, David F Fiorentino, Howard M Shulman, M Kari Connolly, Jerry A Molitor, Gretchen Henstorf, Robert Lafyatis, David K Pritchard and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 78 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 1 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 1 synthesis or guideline pooled it, 184 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. TGFβ signaling pathways in human health and disease.Frontiers in molecular biosciences · 2023
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Endothelial-to-mesenchymal transition in systemic sclerosis.Clinical and experimental immunology · 2021
    Review
  16. Article
  17. Observational
  18. Review
  19. Article
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Jo N FlemingDepartment of Pathology, University of Washington, Seattle, Washington, United States of America. flemij@u.washington.edu
Richard A Nash
D O McLeod
David F Fiorentino
Howard M Shulman
M Kari Connolly
Jerry A Molitor
Gretchen Henstorf
Robert Lafyatis
David K Pritchard
Lawrence D Adams
Daniel E Furst
Stephen M Schwartz
University of Washington · USFred Hutch Cancer Center · USBoston University · USStanford University · USUniversity of California, Los Angeles · USUniversity of California, San Francisco · USVirginia Mason Medical Center · US

Funding

STEM CELL TRANSPLANTATION FOR TX OF AUTOIMMUNE DISEASES-N01AI5419N01AI005419 · NIAID · DUKE UNIVERSITY · PI SULLIVAN, KEITH M · 2000 to 2006
$6.2M
NIAID NIH HHS N01 AI005419NIAID NIH HHS N01-AI-05419
6 · The paper itself

Abstract

backgroundScleroderma is an autoimmune disease with a characteristic vascular pathology. The vasculopathy associated with scleroderma is one of the major contributors to the clinical manifestations of the disease. METHODOLOGY/PRINCIPAL

findingsWe used immunohistochemical and mRNA in situ hybridization techniques to characterize this vasculopathy and showed with morphometry that scleroderma has true capillary rarefaction. We compared skin biopsies from 23 scleroderma patients and 24 normal controls and 7 scleroderma patients who had undergone high dose immunosuppressive therapy followed by autologous hematopoietic cell transplant. Along with the loss of capillaries there was a dramatic change in endothelial phenotype in the residual vessels. The molecules defining this phenotype are: vascular endothelial cadherin, a supposedly universal endothelial marker required for tube formation (lost in the scleroderma tissue), antiangiogenic interferon alpha (overexpressed in the scleroderma dermis) and RGS5, a signaling molecule whose expression coincides with the end of branching morphogenesis during development and tumor angiogenesis (also overexpressed in scleroderma skin. Following high dose immunosuppressive therapy, patients experienced clinical improvement and 5 of the 7 patients with scleroderma had increased capillary counts. It was also observed in the same 5 patients, that the interferon alpha and vascular endothelial cadherin had returned to normal as other clinical signs in the skin regressed, and in all 7 patients, RGS5 had returned to normal. CONCLUSION/SIGNIFICANCE: These data provide the first objective evidence for loss of vessels in scleroderma and show that this phenomenon is reversible. Coordinate changes in expression of three molecules already implicated in angiogenesis or anti-angiogenesis suggest that control of expression of these three molecules may be the underlying mechanism for at least the vascular component of this disease. Since rarefaction has been little studied, these data may have implications for other diseases characterized by loss of capillaries including hypertension, congestive heart failure and scar formation.

Indexed as

Stem Cell TransplantationCapillariesHumansPhenotypeRegenerationScleroderma, Diffuse

Identifiers

PMID18197262
PMCPMC2175530
OpenAlexW2016455961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.